Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Scandinavian Journal of Pain

Official Journal of the Scandinavian Association for the Study of Pain

Editor-in-Chief: Werner, Mads


CiteScore 2018: 0.85

SCImago Journal Rank (SJR) 2018: 0.494
Source Normalized Impact per Paper (SNIP) 2018: 0.427

Online
ISSN
1877-8879
See all formats and pricing
More options …
Volume 16, Issue 1

Issues

Spinal analgesia for severe cancer pain: A retrospective analysis of 60 patients

Lauri Kiehelä
  • Corresponding author
  • Division of Pain Medicine, Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Katri Hamunen
  • Division of Pain Medicine, Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tarja Heiskanen
  • Division of Pain Medicine, Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-07-01 | DOI: https://doi.org/10.1016/j.sjpain.2017.04.073

Abstract

Background and aims

Pain is highly prevalent in advanced cancer, and in some patients refractory to conventional opioid treatment. For these patients, invasive methods of pain relief should be considered. Spinal administration of opioids has been shown to be an effective alternative in refractory cancer pain. The aim of this retrospective study was to collect information on the use of spinal analgesia for cancer pain in Helsinki University Hospital.

Methods

A retrospective patient chart study of all cancer patients with spinal analgesia, either intrathecal or epidural, in a single academic center during a five year period (n = 60).

Results

Forty-four patients were treated with intrathecal (IT) and sixteen with epidural (EP) technique. The most common indication for spinal analgesia was pain refractory to systemic analgesics. Good analgesia was achieved in 50% and 70% of the patients in the EP and IT groups, respectively. The median daily systemic opioid doses prior to spinal analgesia were 874.5 mg and 730.5 mg as oral morphine equivalents in the IT and EP groups, respectively. The systemic opioid could be discontinued or significantly reduced in 83% of the patients. Morphine was used in all IT infusions and most EP infusions, mostly combined with bupivacaine 10mg (IT) or 66mg (EP). The median starting doses of morphine were 3 mg/day (IT) and 19 mg/day (EP) and were increased during titration 27% to 3.8 mg/day (IT) and 91% to 36.2 mg/day (EP). Clonidine (median 0.015 mg/day IT and 0.15 mg/day EP) and/or ketamine were used as adjuvants. The average titration time to stable analgesia was 7–9 days. Numbness in lower limbs was reported by 24% of the IT group. On average, catheters were placed 98 and 61 days before death in IT and EP groups, respectively. No serious complications occurred. Catheter dislocation occurred in 27% of all sixty patients during follow-up. Treatment was discontinued in 10 patients because of catheter dislocation (n =7) or local infection (n = 3).

Conclusions and implications

Spinal administration of opioids is a safe and effective method of pain management in patients with severe cancer pain and can greatly reduce the need of systemic opioids. We are implementing closer collaboration with oncologists to provide spinal analgesia to more patients and earlier to reduce suffering. Catheter dislocation led to discontinuation of spinal analgesia in 17% of the patients and we are evaluating new ways to prevent catheter dislocation. The initial median spinal opioid dose was too low in both groups, and we are now using higher initial doses. A common adverse effect was numbness of the lower limbs, regardless of the relatively low doses of spinal bupivacaine. We now use lower doses and introduce the intrathecal catheter higher at L1–2 to reduce motor blockade at the level of conus.

As an initial intrathecal infusions we suggest: morphine dose calculated using an oral to intrathecal ratio of 1:100 (unless the patient is elderly or already drowsy), clonidine dose 30μg/day and bupivacaine dose 7.5 mg/day.

Keywords: Refractory cancer pain; Spinal opioids; Intrathecal pain management

References

  • [1]

    van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437–49.CrossrefWeb of ScienceGoogle Scholar

  • [2]

    Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation. JAMA 1995;274:1870–3.PubMedCrossrefGoogle Scholar

  • [3]

    Burton AW, Rajagopal A, Shah HN, Mendoza T, Cleeland C, Hassenbusch 3rd SJ, Arens JF. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med 2004;5:239–47.PubMedCrossrefGoogle Scholar

  • [4]

    Aprili D, Bandschapp O, Rochlitz C, Urwyler A, Ruppen W. Serious complications associated with external intrathecal catheters used in cancer pain patients: a systematic review and meta-analysis. Anesthesiology 2009;111:1346–55.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [5]

    Vainio A, Tigerstedt I. Opioid treatment for radiating cancer pain: oral administration vs. epidural techniques. Acta Anesthesiol Scand 1988;32:179–85.CrossrefGoogle Scholar

  • [6]

    Du Pen SL, Kharasch ED, Williams A, Peterson DG, Sloan DC, Hasche-Klunder H, Krembs AW. Chronic epidural bupivacaine–opioid infusion in intractable cancer pain. Pain 1992;49:293–300.CrossrefPubMedGoogle Scholar

  • [7]

    Myers J, Chan V, Jarvis V, Walker-Dilks C. Intraspinal techniques for pain management in cancer patients: a systematic review. Support Care Cancer 2010;18:137–49.CrossrefPubMedWeb of ScienceGoogle Scholar

  • [8]

    Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 2011;25:504–15.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [9]

    Walker PW, Palla S, Pei BL, Kaur G, Zhang K, Hanohano J, Munsell M, Bruera E. Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med 2008;11:1103–8.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [10]

    Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527–34.CrossrefPubMedGoogle Scholar

  • [11]

    Krames ES. Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Symptom Manag 1993;8:36–46.CrossrefGoogle Scholar

  • [12]

    Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, Mangione S. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 2007;23:793–8.Web of ScienceCrossrefPubMedGoogle Scholar

  • [13]

    Gesrin Y, Vainio A, Pégurier AM. Long term intrathecal infusion of morphine in the home care of patients with advanced cancer. Acta Anesthesiol Scand 1997;41:12–7.CrossrefGoogle Scholar

  • [14]

    Deer TR, Caraway DL, Kim CK, Dempsey CD, Steward CD, McNeil KF. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J 2002;2:274–8.PubMedCrossrefGoogle Scholar

  • [15]

    Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine analgesia for intractable cancer pain. Pain 1995;61:391–9.CrossrefPubMedGoogle Scholar

  • [16]

    Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, Caraway D, Cousins M, De Andrés J, Diwan S, Erdek M, Grigsby E, Huntoon M, Jacobs MS, Kim P, Kumar K, Leong M, Liem L, McDowell 2nd GC, Panchal S, Rauck R, Saulino M, Sitzman BT, Staats P, Stanton-Hicks M, Stearns L, Wallace M, Willis KD, Witt W, Yaksh T, Mekhail N. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012;15: 436–64.Web of ScienceCrossrefGoogle Scholar

  • [17]

    Lilius TO, Jokinen V, Neuvonen MS, Niemi M, Kalso EA, Rauhala PV. Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs. Br J Pharmacol 2015;172:2799–813.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [18]

    Yang CY, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine requirement in patients with terminal cancer pain. Can J Anaesth 1996;43:379–83.CrossrefGoogle Scholar

  • [19]

    Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2012;11. CD003351.PubMedGoogle Scholar

  • [20]

    Malhotra VT, Root J, Kesselbrenner J, Njoku I, Cubert K, Gulati A, Puttaniah V, Bilsky M, Kaplitt M. Intrathecal pain pump infusions for intractable cancer pain: an algorithm for dosing without a neuraxial trial. Anesth Analg 2013;116:1364–70.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [21]

    Turner J, Sears J, Loeser J. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin J Pain 2007;23:180–95.CrossrefWeb of ScienceGoogle Scholar

  • [22]

    Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. BMJ 1996;312:823–6.PubMedGoogle Scholar

  • [23]

    Jacox A, Carr DB, Payne R. New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med 1994;330:651–5.CrossrefPubMedGoogle Scholar

  • [24]

    Mastenbroek TC, Kramp-Hendriks BJ, Kallewaard JW, Vonk JM. Multimodal intrathecal analgesia in refractory cancer pain. Scand J Pain 2017;14: 39–43.Web of ScienceCrossrefPubMedGoogle Scholar

About the article

Itämerenkatu 16 A 13, 00180 Helsinki, Finland.


Received: 2017-03-01

Revised: 2017-04-04

Accepted: 2017-04-30

Published Online: 2017-07-01

Published in Print: 2017-07-01


Ethical issues: As a retrospective study, no informed consent was asked. The study was approved by the Finnish Ministry of Social Affairs and Health.

Conflict of interest: The authors have no conflict of interest concerning the study, nor any financial interests.


Citation Information: Scandinavian Journal of Pain, Volume 16, Issue 1, Pages 140–145, ISSN (Online) 1877-8879, ISSN (Print) 1877-8860, DOI: https://doi.org/10.1016/j.sjpain.2017.04.073.

Export Citation

© 2017 Scandinavian Association for the Study of Pain.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Richard J. Bodnar
Peptides, 2019, Page 170223
[2]
Denis Dupoiron, Damien Leblanc, Sybille Demelliez -Merceron, Francois Bore, Valerie Seegers, Pierre Yves Dubois, Marie Pechard, Serge Robard, Thierry Delorme, Sabrina Jubier-Hamon, Gabriel Carvajal, and Nathalie Lebrec
Pain Medicine, 2019

Comments (0)

Please log in or register to comment.
Log in